Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
← catalyst calendarNCT06282575 · readout in 835 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
286estimated
Sites
185
Countries
Argentina, Belgium, Brazil +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-19 | actual | When the study began enrolling |
| Primary completion | 2028-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Biliary Tract Cancer
Interventions
- Drug: Zanidatamab — also filed as ZW25, JZP598, ZIIHERA®
- Drug: Cisplatin
- Drug: Gemcitabine
- Drug: Pembrolizumab
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors
measured Up to 52 months
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed